Stay updated with breaking news from Albert Deisseroth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Olof Lundberg Jr., who spent nearly 50 years as part of the management faculty in the College of Business Administration at the University of New Orleans, died Dec. 28, 2022.
Feb 16, 2021 Tilaciclib is first drug approved for this indication WASHINGTON—The FDA approved tilaciclib (Cosela) to reduce chemotherapy-induced bone marrow suppression in adults. Tilaciclib, which protects bone marrow cells by inhibiting cyclin-dependent kinase 4/6, is the first drug to win FDA approval for this indication. In a prepared statement from the FDA, Albert Deisseroth, MD, PhD, supervisory medical officer in the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research, said, “For patients with extensive-stage small cell lung cancer, protecti...
FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin- dependent kinase 4/6, a type of enzyme. For patients with extensive-stage small cell lung can...